Browsing “ICERICER | EVERSANA”

Is ICER Increasing Influence in the U.S. Over Time?

Recent high-profile product launches have reignited the debate on healthcare costs in the US. The Institute for Clinical and Economic Review (ICER) is an independent research organization that determines value-based price benchmarks. In a recent study, Dr. Stino, Product Manager, examined recent high-profile launches to understand the interaction between ICER value-based price benchmarks and actual […]

ICER’s Unsupported Price Increase Assessment

In October 2019, the Institute of Clinical and Economic Review (ICER) released their first annual report on Unsupported Price Increases of prescription drugs in the United States. The report takes a systematic approach to determine whether certain price increases are justified by new clinical evidence or other factors. Our Health Strategies Insights team conducted a […]

What’s next for ICER? Pharmaceutical pricing watchdog to venture beyond the pill.

Earlier in the month, the Institute for Clinical and Economic Review (ICER) issued a call for public input to help identify and prioritize non-drug topics for ICER assessments in 2020. It may seem like the ICER has always been focused on driving down the price of drugs, conducing health technology assessments to properly calculate the […]

Decoding ICER: Successful Pharma Engagement with ICER for U.S. HTA Review

How pharmaceutical and Biotech companies engaged ICER drives the outcome. Reactive responses to ICER review have led to poor outcomes and numerous downstream impacts to payer access and pricing. Cohesive enterprise engagement has demonstrated significantly better recommendations and less pressure for the US payer community. Unfortunately, ‘reactive-response’ is more common than ‘enterprise engagement.’ KEY SUCCESS […]